169 related articles for article (PubMed ID: 10348763)
1. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.
Nath CE; Shaw PJ; Gunning R; McLachlan AJ; Earl JW
Antimicrob Agents Chemother; 1999 Jun; 43(6):1417-23. PubMed ID: 10348763
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients.
Nucci M; Loureiro M; Silveira F; Casali AR; Bouzas LF; Velasco E; Spector N; Pulcheri W
Antimicrob Agents Chemother; 1999 Jun; 43(6):1445-8. PubMed ID: 10348768
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of amphotericin B in children with malignant diseases.
Nath CE; McLachlan AJ; Shaw PJ; Gunning R; Earl JW
Br J Clin Pharmacol; 2001 Dec; 52(6):671-80. PubMed ID: 11736878
[TBL] [Abstract][Full Text] [Related]
4. Administration of lipid-emulsion versus conventional amphotericin B in patients with neutropenia.
Pascual B; Ayestaran A; Montoro JB; Oliveras J; Estibalez A; Julia A; Lopez A
Ann Pharmacother; 1995 Dec; 29(12):1197-201. PubMed ID: 8672820
[TBL] [Abstract][Full Text] [Related]
5. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients.
Sorkine P; Nagar H; Weinbroum A; Setton A; Israitel E; Scarlatt A; Silbiger A; Rudick V; Kluger Y; Halpern P
Crit Care Med; 1996 Aug; 24(8):1311-5. PubMed ID: 8706484
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia.
Ayestarán A; López RM; Montoro JB; Estíbalez A; Pou L; Julià A; López A; Pascual B
Antimicrob Agents Chemother; 1996 Mar; 40(3):609-12. PubMed ID: 8851579
[TBL] [Abstract][Full Text] [Related]
7. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies.
Caillot D; Reny G; Solary E; Casasnovas O; Chavanet P; Bonnotte B; Perello L; Dumas M; Entezam F; Guy H
J Antimicrob Chemother; 1994 Mar; 33(3):603-13. PubMed ID: 8040124
[TBL] [Abstract][Full Text] [Related]
8. Comparison of conventional and lipid emulsion formulations of amphotericin B: Pharmacokinetics and toxicokinetics in dogs.
Nieto J; Alvar J; Rodríguez C; San Andrés MI; San Andrés MD; González F
Res Vet Sci; 2018 Apr; 117():125-132. PubMed ID: 29272720
[TBL] [Abstract][Full Text] [Related]
9. [Use of amphotericin B in lipid emulsions: does it prevent its toxicity in critically ill patients?].
Hernández G; Altermatt F; Bernucci F; Acuña D; Apablaza F; Valenzuela F; Lefio A; Pérez C; Bugedo G; Castillo L
Rev Med Chil; 2000 Oct; 128(10):1101-7. PubMed ID: 11349508
[TBL] [Abstract][Full Text] [Related]
10. A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients.
Barquist E; Fein E; Shadick D; Johnson J; Clark J; Shatz D
J Trauma; 1999 Aug; 47(2):336-40. PubMed ID: 10452470
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidaemia in neutropenic patients.
Caillot D; Casasnovas O; Solary E; Chavanet P; Bonnotte B; Reny G; Entezam F; Lopez J; Bonnin A; Guy H
J Antimicrob Chemother; 1993 Jan; 31(1):161-9. PubMed ID: 8444659
[TBL] [Abstract][Full Text] [Related]
12. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion versus five percent dextrose solution.
Randall SR; Adams LG; White MR; DeNicola DB
Am J Vet Res; 1996 Jul; 57(7):1054-8. PubMed ID: 8807021
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid.
Shadkchan Y; Zaslavsky Z; Segal E
Med Mycol; 2003 Feb; 41(1):15-9. PubMed ID: 12627800
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of a new lipid-based delivery system for intravenous administration of amphotericin B.
Caillot D; Chavanet P; Casasnovas O; Solary E; Zanetta G; Buisson M; Wagner O; Cuisenier B; Bonnin A; Camerlynck P
Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):722-5. PubMed ID: 1425731
[TBL] [Abstract][Full Text] [Related]
15. Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion.
Dórea EL; Yu L; De Castro I; Campos SB; Ori M; Vaccari EM; Lacaz Cda S; Seguro AC
J Am Soc Nephrol; 1997 Sep; 8(9):1415-22. PubMed ID: 9294833
[TBL] [Abstract][Full Text] [Related]
16. Amphotericin B toxicity reduced by administration in fat emulsion.
Anderson RP; Clark DA
Ann Pharmacother; 1995 May; 29(5):496-500. PubMed ID: 7655134
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
Dutta A; Palazzi DL
Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
[TBL] [Abstract][Full Text] [Related]
18. Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate---fat emulsion in HIV-infected patients with oral candidosis.
Chavanet P; Clement C; Duong M; Buisson M; D'Athis P; Dumas M; Bonnin A; Portier H
Clin Microbiol Infect; 1997 Aug; 3(4):455-461. PubMed ID: 11864156
[TBL] [Abstract][Full Text] [Related]
19. A retrospective study on the efficacy and safety of amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients.
Torre D; Banfi G; Tambini R; Speranza F; Zeroli C; Martegani R; Airoldi M; Fiori G
J Infect; 1998 Jul; 37(1):36-8. PubMed ID: 9733375
[TBL] [Abstract][Full Text] [Related]
20. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels.
Arning M; Kliche KO; Heer-Sonderhoff AH; Wehmeier A
Mycoses; 1995; 38(11-12):459-65. PubMed ID: 8720196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
